Sections |
| Title | Starting Page | Number of Pages |
|---|
| Company Information | 1 | 1 |
| Encysive Pharmaceuticals Inc. (NASDAQ) Symbol : ENCY | 1 | 1 |
| Headquarters | 1 | 1 |
| Fiscal Ends December | 1 | 1 |
| Selected Financial Data | 1 | 1 |
| Business Summary | 1 | 2 |
| Product Glance | 4 | 1 |
| MedTRACK Classification | 4 | 1 |
| Upcoming Milestones | 5 | 1 |
| Date | 5 | 1 |
| Category | 5 | 1 |
| Milestone | 5 | 1 |
| Product Pipeline | 5 | 2 |
| Product Details | 6 | 1 |
| 1. Novastan (argatroban) | 6 | 1 |
| Description | 6 | 1 |
| Therapeutic | 6 | 3 |
| Mechanism of Action | 6 | 3 |
| Partnering Details | 7 | 2 |
| 2. Novastan (argatroban) | 7 | 1 |
| Drug Class | 7 | 1 |
| Current Trial | 7 | 2 |
| 3. Thelin / TBC11251 (sitaxsentan) | 8 | 1 |
| Trial Details | 8 | 5 |
| Last Updated | 13 | 3 |
| Description | 14 | 1 |
| Therapeutic | 14 | 4 |
| Mechanism of Action | 14 | 3 |
| Drug Class | 14 | 1 |
| Current Trial | 14 | 3 |
| Trial Details | 14 | 4 |
| 6. Bimosiamose / TBC1269 | 15 | 1 |
| Partnering Details | 16 | 1 |
| Description | 16 | 7 |
| Drug Class | 16 | 2 |
| 9. Novastan (argatroban) and glycoprotein IIb/IIIa inhibitor | 17 | 1 |
| Mechanism of Action | 18 | 1 |
| Current Trial | 18 | 2 |
| 10. TBC3711 | 18 | 1 |
| Therapeutic | 19 | 5 |
| Drug Class | 19 | 1 |
| Trial Details | 19 | 5 |
| Last Updated | 19 | 1 |
| Partnering Details | 19 | 3 |
| Mechanism of Action | 20 | 1 |
| 14. Novastan (argatroban) | 21 | 1 |
| Drug Class | 21 | 1 |
| Current Trial | 22 | 2 |
| 16. TBC3214 | 22 | 1 |
| Last Updated | 23 | 1 |
| Partnering Details | 23 | 1 |
| Product Revenue | 24 | 1 |
| Qtr 1 Qtr 2 Qtr 3 Qtr 4 Annual | 24 | 1 |
| THELIN | 24 | 1 |
| Recent Financings | 24 | 1 |
| Trademarks | 25 | 1 |
| Corporate Partners | 25 | 1 |
| Deal Category: Miscellaneous Date | 25 | 1 |
| DealValue (in $ MM) | 25 | 2 |
| Deal Category: Product Date | 26 | 1 |
| Management Profile | 27 | 1 |
| John M. Pietruski -- Chairman | 27 | 1 |
| Bruce D. Given -- Chief Executive Officer and President | 27 | 1 |
| George W. Cole -- Chief Operating Officer | 28 | 1 |
| Gordon H. Busenbark -- Chief Financial Officer | 28 | 1 |
| Richard Dixon -- Chief Scientific Officer and Senior Vice President, Research | 28 | 1 |
| Stephen L. Mueller -- Vice President, Finance and Administration | 28 | 1 |
| Derek Maetzold -- Vice President, Marketing and Sales | 28 | 1 |
| Tommy A. Brock -- Vice President, Pharmacology and Preclinical Development | 28 | 1 |
| Heather Giles -- Vice President, Strategic Planning | 29 | 1 |
| D. Jeffrey Keyser -- Vice President, Regulatory Affairs | 29 | 1 |
| Paul S. Manierre -- Vice President, General Counsel and Secretary | 29 | 1 |
| Patrick Ward -- Director, Business Development | 29 | 1 |
| Pamela Mabry -- Director, Human Res | 29 | 1 |
| Ron J. Anderson -- Director | 30 | 1 |
| J. Kevin Buchi -- Director | 30 | 1 |
| Robert J. Cruikshank -- Director | 30 | 1 |
| John H. Dillon -- Director | 30 | 1 |
| Suzanne Oparil -- Director | 30 | 1 |
| James A. Thomson -- Director | 31 | 1 |
| James T. Willerson -- Director | 31 | 1 |
| Denton Cooley -- Scientific Advisory Board Member | 31 | 1 |
| Ferid Murad -- Scientific Advisory Board Member | 31 | 1 |
| Recent Updates | 31 | 1 |
| Company Announcements | 32 | 1 |
| 5/1/2007 -- Encysive Pharmaceuticals Previews European Union Activities for 2007 | 32 | 1 |
| 9/29/2006 -- Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Encysive Pharmaceuticals Inc. | 32 | 1 |
| 6/26/2006 -- Encysive Pharmaceuticals Announces Clinical Organizational Changes | 32 | 1 |
| 2/11/2005 -- Encysive Pharmaceuticals Announces Plans to Release Topline Data From STRIDE-2 Clinical Trial | 32 | 1 |
| 6/3/2004 -- Encysive Updates Ex-North American Licensing Strategy for Thelin | 32 | 1 |
| 5/24/2004 -- New Data on Thelin (TM) Presented at American Thoracic Society's International Conference | 32 | 1 |
| 11/17/2003 -- Encysive Pharmaceuticals Added to NASDAQ Biotechnology Index | 33 | 1 |
| 5/16/2003 -- Texas Biotechnology announces company name change to Encysive Pharmaceuticals | 33 | 1 |
| 6/18/2001 -- Texas Biotechnology to Move to Nasdaq: TXBI is new symbol | 33 | 1 |
| Deals & Alliances | 33 | 1 |
| 4/26/2005 -- Encysive Pharmaceuticals Restructures Agreement with Revotar Biopharmaceuticals | 33 | 1 |
| 10/8/2001 -- Revotar Biopharmaceuticals AG-majority-owned subsidiary of Texas Biotechnology - licenses new research target | 33 | 1 |
| Financials | 34 | 1 |
| 2/7/2007 -- Encysive shares buoyed by GlaxoSmithKline news | 34 | 1 |
| 2/6/2007 -- Encysive Pharmaceuticals Completes $60 Million Note Offering Secured by Argatroban Royalties | 34 | 1 |
| 10/19/2006 -- Encysive Pharmaceuticals Secures Equity Financing Commitment | 34 | 1 |
| 6/15/2005 -- SEC Declares Encysive Resale Registration Statement on Form S-3 Effective | 34 | 1 |
| 3/16/2005 -- Encysive Announces Closing of $130 Million Convertible Senior Note Offering | 34 | 1 |
| 3/11/2005 -- Encysive Announces Pricing of $115 Million of Convertible Senior Notes | 34 | 1 |
| 9/13/2004 -- Encysive Pharmaceuticals Announces Closing of $36.5 Million Stock Offering | 35 | 1 |
| 9/8/2004 -- Encysive Pharmaceuticals Announces Common Stock Offering of 4 Million Shares | 35 | 1 |
| 6/4/2004 -- Encysive Pharma files $150 mln mixed shelf | 35 | 1 |
| 12/23/2003 -- Encysive Pharmaceuticals Announces Closing of $48.6 Million Stock Offering | 35 | 1 |
| 12/3/2003 -- Encysive Pharmaceuticals Announces Public Offering of Common Stock | 35 | 1 |
| 8/20/2003 -- Encysive Pharmaceuticals files $50 million shelf registration statement | 35 | 1 |
| 9/28/2001 -- Update to Texas Biotechnology shareholders; confirms stock repurchase program | 35 | 1 |
| 5/3/2001 -- Texas Biotechnology announces stock repurchase program | 36 | 1 |
| 1/5/2001 -- Texas Biotechnology receives $21.7 million from warrant exercise | 36 | 1 |
| Intellectual Property | 36 | 1 |
| 10/10/2006 -- Shareholder Class Action Filed Against Encysive Pharmaceuticals Inc. by the Law Firm of Schiffrin & Barroway, L | 36 | 1 |
| 9/27/2006 -- Schatz & Nobel, P.C. Announces Class Action Lawsuit Against Encysive Pharmaceuticals, Inc. | 36 | 1 |
| 9/26/2006 -- Lerach Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit Against Encysive Pharmaceuticals Inc. | 36 | 1 |
| Mergers & Acquisitions | 37 | 1 |
| Product Update | 37 | 1 |
| 4/16/2007 -- Encysive Pharmaceuticals Announces Launch of Thelin (Sitaxentan Sodium) in the Netherlands | 37 | 1 |
| 4/2/2007 -- Encysive Pharmaceuticals Announces Launch of Thelin (Sitaxentan Sodium) in Republic of Ireland | 37 | 1 |
| 3/21/2007 -- Encysive Pharmaceuticals Announces Patient Enrollment Initiated for TBC3711 Phase II Study | 37 | 1 |
| 12/18/2006 -- Encysive Pharmaceuticals Announces Launch of Thelin in Germany | 37 | 1 |
| 12/14/2006 -- Encysive Pharmaceuticals Submits Response to FDA For Thelin New Drug Application | 37 | 1 |
| 11/6/2006 -- Encysive Pharmaceuticals Announces Launch of Thelin in United Kingdom | 38 | 1 |
| 11/2/2006 -- Encysive Submits Complete Response to FDA For Thelin New Drug Application | 38 | 1 |
| 6/22/2006 -- Encysive Pharmaceuticals Announces Presentation of New STRIDE-2X Data at EULAR Congress | 38 | 1 |
| 3/23/2006 -- Encysive Pharmaceuticals Delays Studies With TBC3711 | 38 | 1 |
| 1/9/2006 -- Encysive Pharmaceuticals Initiates Dose Ranging Study of TBC3711 | 38 | 1 |
| 10/20/2005 -- Encysive Pharmaceuticals Announces New Thelin Data to be Presented at CHEST 2005 | 38 | 1 |
| 9/14/2005 -- Encysive Pharmaceuticals Announces Interim Topline Data From STRIDE-2 Extension Trial | 38 | 1 |
| 9/6/2005 -- Encysive Pharmaceuticals Presents Thelin Data at European Society of Cardiology | 39 | 1 |
| 7/28/2005 -- Encysive Files for European Marketing Approval of Thelin | 39 | 1 |
| 6/16/2005 -- Encysive to Retain European Rights to Thelin | 39 | 1 |
| 5/25/2005 -- Encysive Pharmaceuticals Submits New Drug Application for Thelin | 39 | 1 |
| 5/22/2005 -- Encysive Announces Six Thelin Abstracts Presented at American Thoracic Society International Conference | 40 | 1 |
| 2/14/2005 -- Encysive Pharmaceuticals Announces Topline Data From Stride-2 Pivotal Trial in PAH | 40 | 1 |
| 10/18/2004 -- New Thelin Data Presented at American College of Rheumatology Meeting | 40 | 1 |
| 10/5/2004 -- Thelin Shows Promise in Patients Failing Bosentan Therapy | 40 | 1 |
| 9/8/2004 -- Encysive Reaches Enrollment Target for STRIDE-2, the Company's Pivotal Phase III Trial for Thelin | 41 | 1 |
| 8/31/2004 -- Data on Thelin Presented at the European Society of Cardiology Annual Congress | 41 | 1 |
| 8/26/2004 -- Encysive Pharmaceuticals Announces Results From Thelin and Viagra Drug Interaction Study | 41 | 1 |
| 7/6/2004 -- Encysive Pharmaceuticals Reiterates Guidance for STRIDE-2 Trial Enrollment | 41 | 1 |
| 9/16/2003 -- Results of Argatroban Plus Glycoprotein IIb/IIIa Inhibitors for interventional heart procedures announced | 42 | 1 |
| 7/15/2003 -- Physician presents results and describes mechanism of action of direct thrombin inhibitor | 42 | 1 |
| 5/19/2003 -- Encysive Pharmaceuticals announces full results for Sitaxsentan in Pulmonary Arterial Hypertension | 43 | 1 |
| 4/23/2003 -- Results of pilot study of Argatroban with Glycoprotein IIb/IIIa Inhibitors announced | 43 | 1 |
| 10/21/2002 -- ICOS-Texas Biotechnology L.P. announces phase IIb/III trial results for Sitaxsentan | 44 | 1 |
| 10/2/2002 -- Texas Biotechnology announces preliminary results for the use of Argatroban as A treatment for Acute Ischemic St | 44 | 1 |
| 7/22/2002 -- ICOS-Texas Biotechnology L.P. provides update on the Sitaxsentan phase IIb/III Pulmonary Arterial Hypertension T | 44 | 1 |
| 6/26/2001 -- Texas Biotechnology and Revotar Biopharmaceuticals AG initiate phase I study with novel Selectin Antagonist 1269 | 45 | 1 |
| 5/30/2001 -- ICOS Corporation and Texas Biotechnology Corporation initiate A pivotal trial in Pulmonary Arterial Hypertension | 45 | 1 |
| 3/14/2001 -- Texas Biotechnology to develop Argatroban as a treatment for Acute Ischemic Stroke | 45 | 1 |
| 3/22/1999 -- Texas Biotechnology resubmits Novastan NDA | 46 | 1 |
| Regulatory | 46 | 1 |
| 3/7/2007 -- Thelin (sitaxentan sodium) Receives Australian Marketing Approval | 46 | 1 |
| 12/28/2006 -- FDA Accepts Encysive's Complete Response To Thelin New Drug Application | 46 | 1 |
| 12/15/2006 -- Encysive Pharmaceuticals' Thelin (sitaxentan sodium) Receives Positive Opinion From Australian Health Authority | 46 | 1 |
| 12/14/2006 -- Encysive Expects to Submit Revised Response to Thelin Approvable Letter Within Several Days | 46 | 1 |
| 12/7/2006 -- Encysive Pharmaceuticals Receives FDA Clearance to Resume Clinical Studies With TBC3711 | 47 | 1 |
| 7/24/2006 -- FDA Issues Approvable Letter for Thelin (Sitaxsentan Sodium); One Outstanding Item Remains | 47 | 1 |
| 6/2/2006 -- Encysive Pharmaceuticals' Thelin (sitaxentan sodium) Receives Positive Opinion From European Authorities | 47 | 1 |
| 5/25/2006 -- Encysive Pharmaceuticals Submits Complete Response to FDA for Thelin New Drug Application | 47 | 1 |
| 3/24/2006 -- Encysive Pharmaceuticals Receives Approvable Letter From FDA for Thelin | 48 | 1 |
| 8/17/2005 -- Encysive Pharmaceuticals' Application for Thelin Accepted for Review By EMEA | 48 | 1 |
| 7/14/2005 -- Encysive Announces PDUFA Date for Thelin New Drug Application in Pulmonary Arterial Hypertension | 48 | 1 |
| 11/11/2004 -- Thelin Gets Orphan-Drug | 48 | 1 |
| 4/9/2002 -- Glaxosmithkline and Texas Biotechnology receive FDA approval for new of Argatroban | 48 | 1 |
| 8/1/2001 -- Texas Biotechnology announces approval of Argatroban in Canada | 48 | 1 |
Tables |
| Title | Starting Page | Number of Pages |
|---|
| of Contents | 3 | 1 |
